Targeted Nutritional Strategies in Early Alzheimer’s Disease

This clinical trial, conducted by the LipiDiDiet consortium and published in Alzheimer’s & Dementia, explores the long-term effects of a specific multinutrient combination (Fortasyn Connect) on individuals with prodromal Alzheimer’s disease. Over a 36-month period, the randomized, placebo-controlled study evaluated cognitive outcomes, brain atrophy, and functional abilities in 311 participants across multiple European countries. The findings provide compelling evidence that nutritional intervention may slow cognitive decline, reduce brain volume loss, and support function in early-stage Alzheimer’s.

Key Takeaways for Clinical Practice

This peer-reviewed publication equips healthcare professionals with insights into:

• The effects of Fortasyn Connect on memory, executive function, and global cognition (e.g., 60% reduction in decline on the NTB 5-item composite)

• Measurable reductions in hippocampal and whole-brain atrophy over 36 months

• Improved performance on Clinical Dementia Rating-Sum of Boxes (CDR-SB), indicating better daily function retention

• A consistent safety profile and high compliance throughout the study

• The growing role of long-term nutritional intervention in managing prodromal Alzheimer’s disease

Access the Full Publication Now

Stay informed and strengthen your clinical approach with this 36-month study from the LipiDiDiet consortium. Click “View Content” to download the full peer-reviewed article and discover how targeted nutrition can support cognitive health in early Alzheimer’s disease.